Workflow
Allurion Technologies, Inc. (ALUR) Reports Q4 Loss, Lags Revenue Estimates
ALURAllurion Technologies(ALUR) ZACKS·2025-03-26 14:16

Company Performance - Allurion Technologies, Inc. reported a quarterly loss of 7pershare,whichwasworsethantheZacksConsensusEstimateofalossof7 per share, which was worse than the Zacks Consensus Estimate of a loss of 5, and an improvement from a loss of 15.75pershareayearago,indicatingasignificantyear−over−yearreductioninlosses[1]−Thecompanypostedrevenuesof15.75 per share a year ago, indicating a significant year-over-year reduction in losses [1] - The company posted revenues of 5.59 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.16%, and down from 8.24millioninthesamequarterlastyear[2]−Overthelastfourquarters,AllurionhassurpassedconsensusEPSestimatesonlyonce,indicatingchallengesinmeetingmarketexpectations[2]StockPerformance−AllurionTechnologies,Inc.shareshavedeclinedapproximately71.18.24 million in the same quarter last year [2] - Over the last four quarters, Allurion has surpassed consensus EPS estimates only once, indicating challenges in meeting market expectations [2] Stock Performance - Allurion Technologies, Inc. shares have declined approximately 71.1% since the beginning of the year, contrasting sharply with the S&P 500's decline of only 1.8% [3] - The current consensus EPS estimate for the upcoming quarter is -22.91 on revenues of 5.6million,andforthecurrentfiscalyear,itis−5.6 million, and for the current fiscal year, it is -18.53 on revenues of $31.63 million [7] Industry Outlook - The Medical - Products industry, to which Allurion belongs, is currently ranked in the bottom 31% of over 250 Zacks industries, suggesting a challenging environment for companies in this sector [8] - The performance of Allurion's stock may be influenced by the overall outlook for the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]